ANTI-HUMAN IL-21 MONOCLONAL ANTIBODIES

• Main Authors: DILLON STACEY R, YI EUGENE C, CECILE M KREJSA, STEPHEN R JASPERS, RAMSDELL FREDERICK J, RIXON MARK W
• Format: Patent
• Language: English; Japanese
• Published: 10.03.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide anti-human IL-21 monoclonal antibodies that inhibit symptoms and biological activities that are expressed as autoimmune disorders and inflammatory disorders and associated with interleukin (IL-21)/IL-21 receptor interaction, as well as methods for using them.SOLUTION: Human anti-human IL-21 monoclonal antibodies and hybridomas producing them are presented. Certain of these antibodies are capable of binding to native human IL-21 protein, recombinant mutant IL-21 proteins, and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, in particular, diseases mediated by T follicular helper cells, B cells, Tcells or T17 cells.SELECTED DRAWING: Figure 3 【課題】自己免疫障害および炎症性障害として発現し、かつ、インターロイキン（IL-21）/IL-21受容体相互作用に関連している症状および生物活性を抑制する抗ヒトIL-21モノクローナル抗体、及びそれらの抗体を使用する方法の提供。【解決手段】ヒト抗ヒトIL-21モノクローナル抗体及びそれらを産生するハイブリドーマ。これらの抗体の内のいくつかは、ネイティブなヒトIL-21タンパク質、組換え変異IL-21タンパク質、及び/又はヒトIL-21のペプチド領域に結合する能力を有する。これらのヒト抗IL-21抗体は、自己免疫疾患及び炎症性疾患、特に、濾胞ヘルパーT細胞、B細胞、TH細胞、又はTH17細胞によって媒介される疾患の治療的処置において有用である。【選択図】図3